Core Viewpoint - A class action lawsuit has been filed against BioAge Labs, Inc. for alleged violations of federal securities laws related to misleading statements made during its IPO and subsequent trial discontinuation announcement [1][2]. Group 1: Lawsuit Details - The lawsuit pertains to BioAge's announcement on December 6, 2024, regarding the discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns, which contradicts earlier claims made during the IPO about the drug's potential in obesity therapy [2]. Group 2: Investor Information - Shareholders who purchased BioAge's securities during the IPO on September 26, 2024, are encouraged to contact the DJS Law Group before March 10, 2025, to participate in the lawsuit [1][3].
Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA